CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 376 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02138747
NCT02138747Phase 4Completed
CompareCT.gov

A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)

Astellas Pharma Global Development, Inc.·interventional·Posted May 15, 2014·Updated Feb 26, 2020

In Brief

A Phase 4 clinical trial evaluating Mirabegron and Tolterodine ER for Overactive Bladder (OAB). Completed, enrolled 376 participants across 30 sites in 2 countries.

Detailed Summary

The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency and incontinence episodes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder (OAB)
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 15, 2014
Enrollment StartJul 24, 2014
Primary CompletionOct 29, 2015
Study CompletionNov 11, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.1 years ago

Interventions

Mirabegrondrug

Oral

Tolterodine ERdrug

Oral